Genetic testing rates of individuals diagnosed with FTD and close biological relatives assessed in the FTD Insights Survey

Less than a quarter of FTD patients received genetic testing despite genetic forms comprising a notable percentage of all FTD cases. Highest rates were reported for individuals diagnosed with FTD with ALS, and rates were higher with known family history. Low rates of genetic testing may exacerbate challenges facing families impacted by FTD such as assessing familial risk of developing FTD and determining eligibility for investigational drugs in development for genetic forms of FTD. Additional research is needed to better understand the accessibility of genetic testing and counseling. Taken together, these findings highlight the need to further raise awareness of genetic FTD with healthcare providers, patients, and biological relatives.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70858_107543
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genetic testing rates of individuals diagnosed with FTD and close biological relatives assessed in the FTD Insights Survey

Stella McCaughey, Devon Chenette, Carrie Milliard, Robert Reinecker et al.
Alzheimer s & Dementia
Amyotrophic Lateral Sclerosis Research
article

Genetic testing rates of individuals diagnosed with FTD and close biological relatives assessed in the FTD Insights Survey

Stella McCaughey, Devon Chenette, Carrie Milliard, Robert Reinecker, T.W. Chow, Penny A Dacks
article en

Abstract

Less than a quarter of FTD patients received genetic testing despite genetic forms comprising a notable percentage of all FTD cases. Highest rates were reported for individuals diagnosed with FTD with ALS, and rates were higher with known family history. Low rates of genetic testing may exacerbate challenges facing families impacted by FTD such as assessing familial risk of developing FTD and determining eligibility for investigational drugs in development for genetic forms of FTD. Additional research is needed to better understand the accessibility of genetic testing and counseling. Taken together, these findings highlight the need to further raise awareness of genetic FTD with healthcare providers, patients, and biological relatives.

Alzheimer s & DementiaVol. 21(S4)
Association for Frontotemporal Degeneration (US), Alector (United States) (US)
Quality Education
Openalex Percentile: Top 31%
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Genetic testing rates of individuals diagnosed with FTD and close biological relatives assessed in the FTD Insights Survey — Stella McCaughey, Devon Chenette, et al. · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS